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Background: Surgery is the mainstay therapy for HPV-induced laryngeal papillomatosis (LP) and adjuvant therapies
are palliative at best. Research revealed that conjugated-linoleic acid (CLA) may improve the outcome of
virally-induced diseases. The effects of Clarinol™ G-80 (CLA) and high oleic safflower oil (HOSF) on children with LP
(concomitant with surgery) were evaluated.
Design: A randomized, double-blinded, crossover and reference-oil controlled trial was conducted at a South
African medical university. Study components included clinical, HPV type/load and lymphocyte/cytokine analyses,
according to routine laboratory methods.
Participants: Overall: ten children enrolled; eight completed the trial; five remained randomized; seven received
CLA first; all treatments remained double-blinded.
Intervention: Children (4 to 12 years) received 2.5 ml p/d CLA (8 weeks) and 2.5 ml p/d HOSF (8 weeks) with a
washout period (6 weeks) in-between. The one-year trial included a post-treatment period (30 weeks) and
afterwards was a one-year follow-up period.
Main outcome measures: Changes in numbers of surgical procedures for improved disease outcome,
total/anatomical scores (staging system) for papillomatosis prevention/viral inhibition, and lymphocyte/cytokine
counts for immune responses between baselines and each treatment/end of trial were measured.
Findings: After each treatment all the children were in remission (no surgical procedures); after the trial two had
recurrence (surgical procedures in post-treatment period); after the follow-up period three had recurrence (several
surgical procedures) and five recovered (four had no surgical procedures). Effects of CLA (and HOSF to a lesser
extent) were restricted to mildly/moderately aggressive papillomatosis. Children with low total scores (seven/less)
and reduced infections (three/less laryngeal sub-sites) recovered after the trial. No harmful effects were observed.
The number of surgical procedures during the trial (n6/available records) was significantly lower [(p 0.03) (95% CI
1.1; 0)]. Changes in scores between baselines and CLA treatments (n8) were significantly lower: total scores [(p 0.02)
(95% CI −30.00; 0.00)]; anatomical scores [(p 0.008) (95% CI −33.00: -2.00)]. Immune enhancement could not be
demonstrated.
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Conclusions: These preliminary case and group findings pave the way for further research on the therapeutic
potential of adjuvant CLA in the treatment of HPV-induced LP.
Keywords: Laryngeal papillomatosis, CLA and HOSF treatments, Disease outcomes, Number of surgical procedures,
Scores of the staging system, Immune responsesBackground
Recurrent laryngeal papillomatosis (RLP) is universally
considered a disease with unmet challenges. It is a trouble-
some and sometimes life-threatening HPV-induced disease
(mostly types 6/11), since it may cause airway obstruction
in infants and children [1-3]. The true incidence of RLP is
unknown, but is estimated between 1 and 4 per 100 000
for USA and Canadian populations. Prevalence is likely
variable and depends on age of presentation, socio-
economic status of the family, and health care systems of
the country or population studied. In South Africa it seems
to be prevalent in poor socio-economic communities of
rural areas with limited health care facilities [4-7]. The
mainstay treatment for this notoriously recurrent disease
remains surgery (laser ablation and forceps or microdebri-
der removal) to retain an open airway. RLP may regress
after several surgical procedures or, unpredictably, progress
towards highly aggressive papillomatosis (rapid growth) or
severe papillomatosis with lung metastasis and dire conse-
quences if left untreated. A tracheotomy is sometimes
required until the disease is manageable. Past adjuvant
therapies for aggressive growth (dietary supplementations,
control of extra-esophageal reflux disease, potent antiviral
and chemotherapeutic agents, as well as photodynamic
therapies) are palliative at best [8-10]. Proper staging of la-
ryngeal papillomatosis (LP) during micro-laryngoscope
examinations is important to follow the clinical course of
the disease for treatment options. In children with RLP im-
munosuppression may influence the clinical course of the
disease and hamper current treatments [11,12]. Until an
appropriate preventive vaccine is available [13], there is on-
going research for cost effective adjuvant therapies to lift
the financial burden this disease places on families and
health care systems. In this regard, adjuvant fatty acid ther-
apy may be considered.
There is continuous interest in the effects of conjugated-
linoleic acid (CLA) and eicosapentaenoic acid (EPA) on
tumor prevention and immune responses, even virally
challenged diseases [14,15]. Research revealed that: CLA
has anti-proliferative and anti-inflammatory potential; it
can induce apoptosis by restoring the PPAR (peroxisome
proliferator activator receptor) balance, by up-regulating
PPAR-γ and α; and that it can modify mediators of innate
and adaptive immune responses, and improve antigen-
specific effector functions of both cellular and humoral
responses to viral infections [14,16,17]. RLP patients arehallmarked by: enhanced palmitic acid (PA) production,
associated with apoptosis and over-expression of PPARδ/β
activity [18]; and altered CD8 + counts and a TH1/TH2 im-
balance, associated with development and severity of this
HPV-induced disease [19]. Based on the above mentioned
information, there is a rationale for CLA to prevent/inhibit
papillomatosis or to inhibit/ameliorate HPV infection and,
thereby, improve immune defenses and disease outcome of
RLP patients [20].
The beneficial use of CLA in human health and diseases
is surrounded by controversy and there is ongoing re-
search [21]. In retrospect, CLA may have different effects
on human disease conditions, depending on: experimental
CLA compositions (different isomers/mixtures) that may
have stimulatory or inhibitory effects on cell proliferation
and immune responses, as in the case of breast cancer
[22]; and ruminant and industrial products of trans fatty
acids may raise cholesterol levels, as in the case of coron-
ary heart diseases [23]. However, there is ample evidence
that specific CLA isomers (cis-9, trans-11 and trans-10,
cis-12) have anti-proliferative and immunomodulatory po-
tential, based on in vitro and in vivo animal and human
studies [14,24-27]. CLA (present in dairy products and
metabolized in the body) is also commercially available as
ClarinolTM G-80 for therapeutic use in clinical trials [14].
A few human clinical trials with CLA on diseases (inflam-
matory and virally-induced conditions) have seen the light
[28,29]. This prompted a preliminary investigation into
the therapeutic use of adjuvant CLA (ClarinolTM G-80) as a
nutritional supplement after surgery in the case of chil-
dren with HPV-induced LP.
The main objective of the study was to evaluate the
effects of CLA (ClarinolTM G-80) and HOSF (high oleic acid
safflower oil) on disease outcomes of LP patients. Aims
were to determine whether CLA and HOSF: reduced the
number of surgical procedures per year for cost effective
treatment; prevented/down-regulated papillomatosis (based
on total scores of the staging system); inhibited/ameliorated
viral infections (based on anatomical scores of the staging
system); and enhanced immune responses (based on T and
B lymphocyte and cytokine counts). Preliminary findings of
this study (case assessments and group evaluations) indi-
cated therapeutic potential for CLA in the treatment of
HPV-induced LP, mainly by: reducing/preventing surgical
procedures per year; and by clearing viral infections in
mildly/moderately aggressive papillomatosis in children
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The study was approved by the Ethics Committee (Faculty
of Health Sciences, University of the Free State). Written
informed consent was obtained from the children and
their parents/guardians prior to the study. Clear instruc-
tions on CLA and HOSF (dosage/time duration/storage)
and scheduled visits, were given to caretakers. Dietary
handouts (picture guidelines) and proper instructions to
follow a basic diet were provided by a nutritionist in an at-
tempt to control the children’s dietary intakes. Patient
sampling was hampered by the number of patients that
presented during the trial period and the age-restriction
included for nutritional purposes. The study period was
limited by shelf-values of the products: two years were
allowed for optimal quality control. Patients (both genders
and aged between 4 to12 years) were recruited from the
Free State Province (rural and urban areas). Hospital
records of all the children were studied for demographic
information and clinical history. Children diagnosed with
other diseases (HIV/diabetes/tuberculosis/inflammatory
diseases) were excluded. All the children were managed
on an out-patient basis, with the exception of one child
(in-ward patient).
Study design
A randomized, double-blinded, crossover and reference-oil
controlled trial was designed. Products (ClarinolTM G-80 and
HOSF) were bottled by a pharmacist (Paraxell, University ofFigure 1 Flow diagram for study design.the Free State) and the computer developed randomization
list was kept confidentially (patients/caretakers/assessors
were blinded). Children had to take 2.5 ml p/d of product
A (or B) for 8 weeks (Period 1) and 2.5 ml p/d of product B
(or A) for 8 weeks (Period 2), with a washout period of
6 weeks in-between. The one-year trial period consisted of
CLA and HOSF treatments with a washout period in-
between (22 weeks), and a post-treatment period (30 weeks).
Ten children enrolled, but eight children completed the
trial (two children did not return after commencement of
the trial). Among the eight children, two patients were
newly recruited with no previous surgical records available.
Five children remained randomized, because three children
started with period 2. The end result was that all the
patients received CLA first in the crossover study (with the
exception of one child), as revealed by the statistician.
Consequently, the baselines with which all the children
started were used for statistical analyses. See flow diagram
of the study design depicted in Figure 1.
Therapeutic products
ClarinolTM G-80 is oil high in cis-9, trans-11 and trans-
10, cis-12 CLA isomers (50:50 ratio), mainly in triglycer-
ide form. ClarinolTM G-80 is made from natural safflower
oil by a gentle, proprietary process and contains concen-
trated CLA, rosemary extract and vitamin E. High qual-
ity CLA when consumed at 3–6 g/d is safe for human
consumption [30]. A dosage of 2.5 ml/d equals 2.5 g/d.
HOSF is often used as a reference-oil for lipid studies
and clinical trials [31,32]. CLA is known for its ability to
induce apoptosis and to enhance immune responses
[14]. HOSF is known for its nutritional benefits and its
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tions. Although olive oil can prevent cell proliferation or
boost the immune system, disparate findings with oleic
acid (main component of olive oil) were encountered in
the literature [33,34]. Decision-making for dosage and
time durations (both CLA and HOSF treatments) to
conduct this trial was within boundaries for previous
human trials.
Surgical procedures and disease staging
Before commencement of the trial all the children were
endoscopically diagnosed, staged for disease assessment,
and received surgical procedures. All the children were
subjected to micro-laryngoscopic examinations during
the trial (before and after the first treatment/before and
after the second treatment/during washout and post-
treatment periods) for clearance of airway passages, if
required. All surgical procedures (before trial/during
each treatment/after trial/after follow-up period) were
carefully documented. Disease assessment was done
according to clinical, anatomical and total scores of the
Derkay staging system. The total score (i.e. summation
of clinical and anatomical scores) gives a fair account of
the overall disease condition; the clinical score reflects
disease symptoms; and the anatomical score relates to
the extent of viral infection. Score sheets for disease sta-
ging: before and after each treatment; after the trial; and
upon emergency during the trial, were completed and
filed. Patients were scheduled for visits to the otorhino-
laryngology clinic on a monthly basis during treatment
periods to monitor medicine intakes, general well-being
of the children, and status quo of the disease. Otherwise,
children were seen on emergency.
Biopsies and blood specimen
Biopsies of the papillomata (size varied, according to avail-
ability) were taken endoscopically (before and after the
trial) for HPV typing and viral load determinations. Blood
specimens were collected for T lymphocyte, B lymphocyte
and cytokine analyses (before and after each treatment, as
well as after the trial). All specimens were taken according
to strict protocol and immediately transferred for routine
laboratory analyses. The study components are presented
in Figure 1.
Determination of HPV types and viral loads
The HPV type and viral load of each patient were
required for correlation with aggressiveness and disease
outcome. The techniques followed for HPV typing were
performed according to a method described in the litera-
ture [35]. Papilloma biopsies were immediately pro-
cessed or frozen at −20°C, until analyzed. Briefly, total
DNA was extracted from biopsies using QIAamp DNA
Mini Kit, according to the manufacturer’s instructions(QIAGEN Inc., Valencia, CA). Consensus primers, previ-
ously identified for a region of the genome that is well
conserved for most HPV types, were used to amplify a re-
gion of the major viral capsid L1 gene, using a standard
PCR technique. The primer pair (designated MY09 and
MY11) target and amplify a 469 base pair (bp) region be-
tween positions 6722 to 7190 of the HPV-6 genome. The
nucleotide sequence of amplicons was determined using
Big DyeTM Terminator Sequencing Ready Reaction kits with
AmpliTaq DNA polymerase FS (Applied Biosystems, Foster
City, CA), according to the manufacturer’s instructions.
Nucleotide sequence data was edited using ChromasPro
Version 1.42 and aligned using Clustal Version X1.8. The
genotypes of HPV were determined by BLAST analysis.
HPV viral loads were determined on baseline samples and
samples submitted after the one year trial period. Quantifi-
cation of HPV viral loads was determined by use of a rela-
tive quantitative real time PCR based on SYBR Green
technology. The viral load was determined using the pri-
mers mentioned and a modification of methods described
in the literature [36,37], in which amplification of the B glo-
bin gene was used as an external control and the viral load
expressed as a ratio of HPV to total DNA.Lymphocyte assay
Peripheral blood specimens were collected in purple stop-
per tubes (sterile K3 EDTA vacutainers) and analyzed
within 24 h by flow cytometry. Mature human T-
lymphocytes (CD3+), suppressor/cytotoxic T-lymphocyte
subsets (CD3 +CD8+), and helper/inducer T-lymphocytes
subsets (CD3 +CD4+) were identified and determined in
erythrocyte-lysed whole blood. T lymphocyte counts were
determined by a BD FACS Caliber Flow Cytometer and the
use of MultiTESTTM reagents and TruCOUNT tubes,
according to manufacturer’s instructions Results were
reported as the percentage of positive cells per lymphocyte
population or as the number of positive cells/μl of blood
(absolute count) by using MultiSETTM software.Immunoglobulin assay
Peripheral blood specimens were collected in yellow stopper
tubes (BD Vacutainer® SSTTM II Advance) without stasis,
and centrifuged within 2 h to separate serum from cells for
immediate immunoglobulin (Ig) analyzes. Techniques fol-
lowed according to manufacturer’s instructions were: IgG,
IgA and IgM were analyzed on the Dade Behring BN Pro-
spect Nephelometer by using an immunonephelometric
technique with reagents from Dade Behring (N Antisera to
Human immunoglobulins G, A and M); and IgE was ana-
lyzed using a particle-enhanced immunonephelometric
technique with reagents from Dade Behring (N Latex IgE
mono). Results were evaluated by comparison with a
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control procedure was performed to ensure optimal results.
Cytokine assay
Peripheral blood specimens were collected in green stopper
tubes (vacutainers containing heparin as anti-coagulant) for
cell culturing. Peripheral blood mononuclear cells (PBMCs)
were cultured in a medium (containing L-glutamine, 20%
fetal calf serum and 0,004 mg/ml gentamycin) stimulated
with phytohaemagglutinin M (PHA-M) and then centri-
fuged to obtain the supernatant for cytokine analyses,
according to methods described in the literature [31,32].
The cytokine assay was performed by flow cytometry with
the use of cytometric bead arrays (Becton Dickinson),
according to manufacturer’s instructions. A cytometric
bead array kit (Human Th1/Th2 Cytokine Kit II, BD
Biosciences, San Jose, California) was used, and results were
analyzed with BD FCAP ArrayTM software (Cat.No.641488).
Concentrations of interleukin (IL-2, IL-4, IL-6, IL-10),
tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ)
levels were measured. The limit of detection for each cyto-
kine was defined as the corresponding concentration at two
standard deviations above the median fluorescence of 20
replicates of the negative control (0 pg/ml).
Statistical analyses
For statistical comparisons the Mann–Whitney or paired
non-parametric signed rank tests were used where ap-
plicable. Results were summarized by medians, quartiles,
minima and maxima and the differences between med-




Demographic information regarding gender, age, disease
duration, and residential area of the patients (cases 1 to
8) is presented in Table 1. Children were diagnosed upon
hospital admittance and onset of the disease (age of theTable 1 Demographic information of laryngeal
papillomatosis patients




Case 1 Male 4 yrs 11 yrs ± 7 yrs Rural
Case 2 Male 6 yrs 8 yrs ± 2 years Rural
Case 3 Male 6 yrs 11 yrs ± 5 years Urban
Case 4 Female 8 yrs 9 yrs ± 1 year Urban
Case 5 Male 9 yrs 9 yrs New patient Rural
Case 6 Male 7 yrs 7 yrs New patient Rural
Case 7 Female 1 yr 4 yrs ±3 years Urban
Case 8 Male 3 yrs 11 yrs ±8 yrs Ruralchild at the time) was not always assessable for correl-
ation with disease outcome. All the children underwent
micro-laryngoscopic surgery with cold steel debulking
and/or CO2 laser removal, with the exception of one
child (Case 1) where a microdibrider was also used. Only
one child (Case 1) had a tracheotomy several years prior
to the trial. None of the patients previously received any
adjuvant therapies, with the exception of one child (Case 1)
who had zinc supplementation three years prior to the trial.
Disease outcomes were assessed: firstly, as cases (1 to 8);
and secondly, as groups (where applicable for different
components of the study).
Number of surgical procedures
Case assessments
During each treatment (CLA and HOSF) none of the chil-
dren required surgical procedures. After the one-year trial
period two children (cases 1 and 2) (25%) had surgical pro-
cedures during the post-treatment period, while six chil-
dren (cases 3/4/5/6/7/8) (75%) had no surgical procedures.
After the one-year follow-up period three children (cases
1/2/6) (37.5%) had recurrence (several surgical procedures)
and five children (cases 3/4/5/7/8) (62.5%) recovered. Dur-
ing the one-year follow-up period four of the five children
(cases 3/5/7/8) had no surgical procedures, but one child
(case 4) required one more surgical procedure (one month
after the trial) before recovery. All the children received
surgical procedures before each treatment, with the excep-
tion of cases 3 and 6 who were clear before HOSF treat-
ment. The numbers of surgical procedures (before trial/
after each treatment/after trial/after follow-up period) are
indicated in Table 2.
The washout period between CLA and HOSF treatments
was considered sufficient [31]. No adverse effects were
observed with the sequence of treatments (case 8 received
HOSF first), despite a previous in vitro study that indicated
interference when CLA was supplemented after oleic acid
[38]. Case 1 (severely aggressive with lung metastasis) and
case 2 (highly aggressive with rapid recurrence) had lower
or a remarkable lower number of surgical procedures dur-
ing the trial (post-treatment period), compared with those
before the trial (average per year). Case 4 who recovered
during the follow-up period was considered more aggres-
sive before the trial, based on the average number of surgi-
cal procedures per year (> 4 per year) this child received;
Case 6 (a newly recruited patient) had rapid recurrence
after the trial and received 6 surgical procedures during
the one-year follow-up period (see Table 2). The outcome
of case 6 correlated with its viral status (see viral
infections).
Group evaluation
Among the study group two patients were newly
recruited with no surgical records available. For those
Table 2 Numbers of surgical procedures and disease outcomes
Patient Before trial During CLA During HOSF During trial During follow-up Disease outcomes
Case 1• 7.4 0 0 5 10 Recurrence
Case 2• 10.2 0 0 2 12 Recurrence
Case 3 2 0 0 0 0 Recovered
Case 4◦ 4.6 0 0 0 1 Recovered
Case 5* 0 0 0 0 0 Recovered
Case 6* 0 0 0 0 6 Recurrence
Case 7 2.7 0 0 0 0 Recovered
Case 8 1.1 0 0 0 0 Recovered
• Cases 1 and 2 received surgical procedures during post-treatment period of one-year trial; ◦ Case 4 recovered one month after trial; * Cases 5 and 6 were new
patients with no available surgical records.
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cal procedures during the one-year trial, compared with
those before the trial over a period of 13–105 months
(calculated from dates of diagnoses), was significantly
lower (p 0.03) (95% CI 1.1; 0) (Table 3). This finding
may be in favor of the beneficial use of CLA to reduce
the number of surgical procedures for cost effective
treatment of this notoriously recurrent disease.Table 4 HPV types and viral loads of laryngeal papilloma
biopsiesViral infections
Children were typed as HPV6 or 11. Overall: cases typed
HPV6/11 with lower viral loads and no surgical proce-
dures during the trial recovered; while those typed
HPV6/11 with higher viral loads and/or no surgical pro-
cedures during the trial had recurrence. HPV11 infec-
tion is considered to confer more aggressive growth. Of
significance may be the fact that case 7 (HPV11/low
viral load before the trial) recovered during the trial,
while case 6 (HPV11/highest viral load before the trial)
had recurrence after the trial. Case 4 (HPV6) who recov-
ered during the one-year follow-up period (20 weeks
later/one more laser treatment) had a high viral load
after the one-year trial, while case 2 (HPV6) (marked by
rapid recurrence before and after the trial) had the high-
est viral load after the trial. HPV typing and viral loading
(before and after the trial) for each patient is summar-
ized in Table 4. Viral loads before and after the trial wereTable 3 Surgical procedure values before and after the
trial (n6)
Period MED LQ UQ MIN MAX
Before trial 3.7 2 7.4 1.1 10.2
After trial 0 0 1 0 5
MAX: maximum MED: median; MIN: Minimum; Log diff: log difference LQ:
lower quartile; UQ: upper quartile.
Significant reduction in surgical procedures during trial (12 month period)
(p 0.03, 95% CI 1.1; 0), compared with average surgical procedures per year
before the trial (from diagnosis: 13–105 month period).not significantly different (p 0.95) (95% CI8 -0.80; 2.31)
(Table 5). The role of viral loading rather than type for
disease aggressiveness needs further clarification.Scores of the staging system
Case assessments: total scores
Total scores (after each treatment/after the trial) give an
overall account of how papillomatosis was prevented or
down-regulated in each child (Table 6). Overall: papillo-
matosis was prevented in cases 3/4/5/6/8 after CLA
treatment; cases 3/4/7 after HOSF treatments; and Case
7 after the trial. After CLA treatment a decrease in total
scores occurred among all the children, except case 2
(same score); after HOSF treatment total scores varied,
but there appeared to be a slight decrease in patients
with lower total scores (except case 6). This patient was
considered potentially more aggressive before the trial
(HPV type 11/highest viral load among the group) (see
Table 4). CLA treatment prevented papillomatosis effect-
ively in those patients who received CLA first (cases 3/
4/5/6) and the patient who received HOSF first (case 8)
in the crossover study. Children (cases 3/5/7/8) with
total scores of seven and less recovered after the trial
(without further treatment), except case 4 (see Table 6).Patients HPV
type
Viral load before trial Viral load after trial
HPV: DNA Log-value HPV: DNA Log-value
Case 1 HPV11 76.14 1.88 11.92 1.08
Case 2 HPV6 1620 3.21 227000 5.35
Case 3 HPV6 369 2.57 690 2.84
Case 4 HPV6 229 2.36 46500 4.67
Case 5 HPV6 1900 3.28 565 2.75
Case 6 HPV11 59900 4.78 11700 4.07
Case 7 HPV11 1.18 0.55 Clear Clear
Case 8 HPV6 1.23 0.0899 Clear Clear
Table 5 Viral load log values before and after the trial
(n8)
Period MED LQ UQ MIN Max
Baseline 2.47 1.21 3.25 0.09 4.78
End trial 2.8 0.54 4.37 0.00 5.35
Log diff −0.31 −0.63 1.21 −0.80 2.31
MAX: maximum MED: median; MIN: Minimum; Log diff: log difference LQ:
lower quartile; UQ: upper quartile.
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trial (> 4 surgical procedures per year) (see Table 2).
Case assessments: anatomical scores
Anatomical scores after each treatment give an account of
how viral infections were cleared or inhibited (Table 6). A
summary of the anatomical sites and sub-sites provide
insight into the areas of infection before and after the trial
(Table 7). Overall: viral infections were cleared in cases
3/4/5/6 after CLA treatment; cases 3/6 after HOSF treat-



















Before CLA 3 2 1 1 1 0 4 1
After CLA 6 4 0 0 0 0 1 0
Before
HOSF
9 10 0 1 1 0 0 1
After HOSF 5 1 0 0 1 2 0 0


















Before CLA 43 28 12 12 3 5 10 7
After CLA 10 26 0 0 0 0 2 2
Before
HOSF
39 12 0 12 8 0 2 7
After HOSF 47 15 0 0 1 12 0 2


















Before CLA 46 30 13 13 4 5 14 8
After CLA 16 30 0 0 0 0 3 0
Before
HOSF
48 22 0 13 9 0 2 8
After HOSF 52 16 0 0 2 14 0 3
After trial 53 22 7 4 6 37 0 7
All the children received CLA first (except case 8) in the double-blinded,
crossover study.primarily infection of the larynx (3 and less sub-sites)
recovered after the trial (cases 3/4/5/8 typed HPV6)
(Table 7). Main trends observed were: case 7 (HPV11/low-
est viral load before the trial) recovered sooner (after both
treatments); case 4 (HPV6/highest viral load after the trial)
was clear after both treatments, presented with a low score
after the trial, but recovered early during the follow-up
period. The disease condition of case 1 (multi-site infec-
tions) and that of case 2 (multiple laryngeal sub-site infec-
tions) remained approximately the same as before the trial
(Table 7). The prognosis of case 1 with lung metastasis is
poor. The disease condition of case 2 can be ascribed to
ill-health (malnutrition) and poor parental care, as wit-
nessed during scheduled visits to the clinic. The immuno-
competence of cases 1 and 2 were questionable.
In retrospect, the effects of CLA (and HOSF in this
crossover study) on total and anatomical scores were
restricted to cases with low total scores. Research
revealed that olive oil (rich in oleic acid) has potential to
inhibit CO2 activity and Bcl oncogene-expression during
early tumorigenesis, but this could not be confirmed for
pure oleic acid [39]. Taken in consideration the benefits
of oleic acid and safflower oil in HOSF, it is possible that
both CLA and HOSF may have contributed to disease
outcomes during this crossover trial, depending on dis-
ease aggressiveness. Future research with CLA and
HOSF requires parallel investigations for elucidation of
their individual effects on LP patients.
Group evaluations: total and anatomical scores
Changes in total scores between baselines and CLA
treatment were significantly lower (p < 0.02) (95% CI
−30.00; 0.00), but not significantly different between
baselines and HOSF treatment (p 0.47) (95% CI −13.00;
14.00). Differences in changes between treatments were
also not significantly different (p 0.13) (95% CI −34.00;
6.00). Changes in anatomical scores were significantly
lower between baselines and CLA treatment (p 0.008)
(95% CI −33.00; -2.00), but not significantly different be-
tween baselines and HOSF treatment (p 0.95) (95% CI
−12.00; 12.00). Differences in changes between treat-
ments were significantly higher (p 0.05) (95% CI −41.00;
4.00). Changes between baselines and the end of the trial
for total and anatomical scores were not significantly dif-
ferent. Group values for total and anatomical scores are
presented in Tables 8 and 9.
The significant lower total scores after CLA treatment
indicate CLA potential to prevent/down-regulate papillo-
matosis during treatment. The significant lower anatom-
ical scores after CLA treatment indicate CLA potential to
inhibit/ameliorate viral infections during treatment. The
significant higher anatomical scores between treatments
(CLA and HOSF) also indicate that CLA treatment was
effective in inhibiting viral infections during treatment,
Table 7 Summary of anatomical site and sub-site infections before and after the trial
Case 1 Before: Larynx (aryepiglottis fold/false and true vocal cords/arytenoids/anterior and posterior commissures/sub-glottis) and trachea/lungs
After: Larynx (aryepiglottis folds/false and true vocal cords/anterior and posterior commisure/sub-glottis) and trachea/bronchi/lungs
Case 2 Before: Larynx (aryepiglottis folds/false and true vocal cords/arytenoid/anterior commissure/sub-glottis)
After: Larynx (aryepiglottis fold/false vocal cords/true vocal cord)
Case 3 Before: Larynx (true vocal cords/anterior and posterior commissures)
After: Larynx (true vocal cord/anterior commissure)
Case 4 Before: Larynx (false and true vocal cords/arytenoid), palate and pharynx
After: Larynx (true vocal cords)
Case 5 Before: Larynx (true vocal cords/anterior commissure)
After: Larynx (false vocal cords/true vocal cord)
Case 6 Before: Larynx (aryepiglottis fold/arytenoid/posterior commissure) and pharynx
After: Larynx (laryngeal epiglottis surface/aryepiglottis folds/false and true vocal cords/arytenoids/anterior and posterior commissures)
Case 7 Before: Larynx (false vocal cord/true vocal cord/anterior and posterior commissures)
After: Clear
Case 8 Before: Larynx (laryngeal epiglottis surface/aryepiglottis fold/arytenoid/anterior commissure)
After: Larynx (anterior and posterior commissures)
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http://www.lipidworld.com/content/11/1/136but not afterwards. The question that can be raised is did
CLA contribute to disease remission/recovery or was it
spontaneous remission/recovery? There is ample evidence
in the literature that CLA can prevent colon polyps
(growths) after surgery [16,24,40]. It was also reported that
CLA can significantly improve the conditions of rheuma-
toid arthritis patients (same dosage/same CLA mixture of
isomers) [28]. Pre-clinical and clinical trials also confirmed
the beneficial use of CLA in the treatment of virally-Table 8 Total score values of the staging system (n8)
Baseline scores
MED LQ UQ MIN MAX
13.00 6.50 22.00 4.00 46.00
Changes in scores after CLA treatment
Med LQ UQ Min Max
0.00 0.00 9.50 0.00 30.00
Changes in scores between baseline and CLA treatment
MED LQ UQ MIN MAX
−9.50 −13.00 −4.50 −30.00 0.00
Changes in scores after HOSF treatment
Med LQ UQ Min Max
2.50 0.00 15.00 0.00 52.00
Changes in scores between baseline and HOSF treatment
Med LQ UQ Min Max
−3.50 −6.50 2.00 −13.00 14.00
Differences in changes between treatments
Med LQ UQ Min Max
−6.00 −16.00 1.50 −34.00 6.00
MAX: maximum MED: median; MIN: Minimum; LQ: lower quartile; UQ: upper
quartile.induced asthma [41]. It is feasible that CLA therapy (after
surgery) may be useful in the treatment of HPV-induced
LP patients, but more extensive research that includes dis-
tinct categories for aggressiveness concomitant with full
surgical history is required for proper assessments.
Disease outcomes and aggressiveness
There is a bevy of criteria for disease aggressiveness,
namely: HPV type 11 and/or high viral load; frequentTable 9 Anatomical score values of the staging system (n8)
Baseline scores
MED LQ UQ MIN MAX
11.00 6.00 20.00 3.00 43.00
Changes in scores after CLA treatment
Med LQ UQ Min Max
0.00 0.00 6.00 0.00 26.00
Changes in scores between baseline and CLA treatment
MED LQ UQ MIN MAX
−7.50 −12.00 −4.00 −33.00 −2.00
Changes in scores after HOSF treatment
Med LQ UQ Min Max
1.50 0.00 13.50 0.00 47.00
Changes in scores between baseline and HOSF treatment
Med LQ UQ Min Max
−1.00 −6.00 5.50 −12.00 12.00
Differences in changes between treatments
Med LQ UQ Min Max
−5.50 −14.50 −1.00 −41.00 4.00
MAX: maximum MED: median; MIN: Minimum; LQ: lower quartile; UQ: upper
quartile.
Figure 2 CD8+ counts before and after treatments.
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http://www.lipidworld.com/content/11/1/136surgical procedures (> 4 surgical procedures per year); dis-
ease extent (multiple site/sub-site infections); rapid recur-
rence (repeated surgical procedures); early age of onset;
and prolonged disease duration [1-3]. The patients of this
study had either mildly/moderately or highly/severely ag-
gressive papillomatosis, according to lower or higher total
scores (see Table 6).
Disease outcomes of the patients (cases 1 to 8) based
on criteria for aggressiveness before and after the trial
are summarized:
 Case 1 (HPV11): severely aggressive before the trial
(HPV type/high total score/repeated surgical
procedures); recurrence during post-treatment
period, after the trial and during the follow-up
period (multi-site and sub-site infections/repeated
surgical procedures).
 Case 2 (HPV6): highly aggressive before the trial
(high total score/rapid recurrence/repeated surgical
procedures); recurrence during post-treatment and
follow-up periods (higher viral load after
trial/repeated surgical procedures).
 Case 3 (HPV6): moderately aggressive before the trial
(low viral load/moderate total score/< 4 surgical
procedures per year); recovered after the trial
(low viral load/low total score/no surgical procedures).
 Case 4 (HPV6): potentially more aggressive before
the trial (>4 surgical procedures per year/moderate
total score); recurrence after the trial (higher viral
load/low total score/no surgical procedures), but
recovered after one more surgical procedure
(one month later during follow-up period).
 Case 5 (HPV6): Mildly aggressive before the trial
(low total score); recovered after the trial (lower viral
load/low total score/no surgical procedures).
 Case 6 (HPV11): potentially more aggressive before
the trial (HPV type/high viral load); highly
aggressive after the trial (high viral load/high total
score/rapid recurrence/repeated surgical procedures
during follow-up period).
 Case 7 (HPV11): potentially more aggressive before
the trial (HPV type/moderate total score); recovered
after the treatment periods (low viral load/no
surgical procedures).
 Case 8 (HPV6): mildly aggressive before the trial (low
viral load/low total score/< 4 surgical procedures per




Upon studying the lymphocyte and cytokine profiles of
the cases (after each treatment/after the trial) it was clear
that: counts varied little; were within available referenceranges; were mostly inconsistent; and mostly no correla-
tions with disease aggressiveness occurred (data not
shown) (Additional files 1, 2 and 3). This is to be expected,
because of the few cases studied. Another study with CLA
supplementation on human rhinovirus (HRV) infection
also showed inconsistent results, mainly because of insuffi-
cient patient numbers for correlations with illness symp-
toms within the group [29]. In the literature it is reported
that CLA supplementation can increase CD8+/IL-2/IL-10
counts in humans [14]. Previous studies on LP patients
reported on the significance of CD8+/IL-2/IL-10 in the
clinical course of this disease [19,42,43]. Therefore, the
current study focused specifically on changes in CD8+
IL-2/IL-10 counts after treatments. Main trends that
occurred among the LP cases are briefly mentioned. An
increase in CD8+ counts was observed after CLA treat-
ment in some patients (cases 3 to 8) (Figure 2). The in-
crease in CD8+ counts may reflect an improved immune
response for these children that lasted beyond the period
of treatment, but were short-lived. It was established that
the effects of CLA-60 supplemented diet (compared with a
soybean diet) on immune cell phenotype (i.e. numbers of
CD8+ counts) lasted approximately 2 months after the prod-
uct was withdrawn, but effector functions (i.e. antigen-
stimulated proliferation and cytotoxicity) disappeared earlier
(approximately 3 weeks), based on an animal model study
where pigs were inoculated with a virus [44]. With respect
to IL-10 counts, it can be mentioned that: case 4 (HPV6/
high viral load after trial/low total score after trial) pre-
sented with a lower IL-10 count after the trial, but recov-
ered during the follow-up period; while case 6 (HPV11/
highest viral load before the trial/high total score after the
Table 10 CD8 + and interleukin-2 and −10 count values
(n6)
Baseline counts
Subsets MED LQ UQ MIN MAX
CD 8 715 513.5 904.5 266 1373
IL-2 7.18 5.85 8.5 4.51 9.14
IL-10 136.22 30.04 214.39 0 234.86
Difference in counts after CLA treatment
Subsets MED LQ UQ MIN MAX
CD 8 45 −35.5 275 −334 832
IL-2 0.73 −1.16 1.72 −3.21 5.21
IL-10 4.31 −76.74 62.57 −211.63 181.03
Difference in counts after HOSF treatment
Subsets MED LQ UQ MIN MAX
CD 8 16.5 −261.5 155.5 −470 227
IL-2 −0.74 −7.16 1.01 −10.36 5.21
IL-10 54.27 −77.79 352.93 −125.04 615.78
Difference in counts between CLA and HOSF treatments
Subsets MED LQ UQ MIN MAX
CD 8 290.5 −103.5 454 −439 644
IL-2 1.85 −2.86 6 −4.22 15.57
IL-10 −46.05 −564.56 138.28 −579.81 187.61
Difference in counts between baselines and end of the trial
Subsets MED LQ UQ MIN MAX
CD 8 270 209.5 395 −118 1327
IL-2 −2.45 −5.85 20.07 −7.01 144.39
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but had recurrence during the follow-up period (Figure 3).
However, all the other children (cases 3/5/7/8) with higher
IL-10 counts after the trial (study component excluded
cases 1 and 2) recovered (Figure 3). It is feasible that
enhanced IL-10 may successfully combat viral infections
in mildly/moderately aggressive papillomatosis, but not in
potentially very aggressive papillomatosis marked by
higher viral loading.
Group evaluations
Comparisons of CD8+/IL-2/IL-10 counts, namely: changes
in counts between baselines and each treatment; the differ-
ence in changes between treatments; and changes between
baselines and the end of the trial, showed that none of the
counts were significantly different, with one exception. Sig-
nificantly higher IL-10 counts (p 0.03) (95% CI 66.33;
1011.57) (n6 patients) occurred after the one-year trial
(Table 10). Of significance is that RLP patients are charac-
terized by high IL-10 levels [42]. It is also known that
enhanced IL-10 has the potential to inhibit other cytokines
(IL-2/IL-4/IL-6/IL-8 and TNF-α) [45].
Upon studying the literature, studies with CLA supple-
mentation on healthy individuals without or with vaccina-
tions were encountered. The effects of CLA supplementation
on immune function in young healthy humans were as fol-
low: one study demonstrated enhanced IL-10 levels (dos-
age of 3 g/day CLA and observation period of 12 weeks)Figure 3 IL-10 counts before and after the trial. Case 6
(HPV11/highest viral load before trial) had highest IL-10 count after
trial; Case 4 (HPV11/very low viral load before trial) had lowest IL-10
count after trial.
IL-10 107.82 82.39 521.35 66.33 1011.57
MAX: maximum MED: median; MIN: Minimum; LQ: lower quartile; UQ: upper
quartile.[32], while another study demonstrated an increase in T
lymphocyte proliferation, but not lymphocyte subpopula-
tions (dosage 2.5 g/d and observation period of 8 weeks)
[31]. The effects of CLA supplementation on healthy indi-
viduals after vaccinations were as follow: healthy men after
hepatitis B vaccination (dosage of 3 g/day and observation
period of 12 weeks) had improved adaptive (humoral) im-
mune response (an increased seroprotection rate), but
other immune functions were not affected [14,46]; healthy
women after influenza vaccination (dosage of 3 g/day and
observation period of 63 days) had no enhanced immune
responses [14,47]. The current trial on HPV-induced LP
patients also failed to demonstrate immune enhancement
with CLA supplementation after surgery (dosage of 2.5 g/d
and observation period of 8 weeks). Discrepancies among
previous studies were attributed to different methods, sup-
plementation procedures and subjects used. In the case of
the current preliminary study stress (repeated surgical
procedures) may have played a role and the small patient
number definitely undermined correlations and the statis-
tical power of the trial.
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have papilloma recurrence and what role has enhanced
IL-10 to play in this phenomenon? RLP is considered a
complex multigene disease, manifesting as a tissue and
HPV-specific immune deficiency, which prevents effective
clearance and/or control of HPV6/11 infections [48].
Advanced studies revealed that polymorphisms in the IL-
10 gene proximal promotor region are known to influence
the production of IL-10 [45]. However, IL-10 is considered:
an ant-inflammatory agent; and a critical modulator of the
TH1/TH2 balance that stimulates functions of innate and
TH2-related (humoral) immunity, but suppresses TH1-
related (cellular) immune responses [45]. It is therefore
conceivable that: enhanced IL-10 can fight viral infections
effectively in mildly/moderately aggressive papillomatosis;
and that enhanced IL-10 levels during prolonged exposure
to viral infections in highly/severely aggressive papilloma-
tosis apparently tilt the scale towards a TH2 disease, with
consequent immnunosuppression and papilloma recur-
rence. The link between enhanced IL-10 levels and clear-
ance or failure to clear viral infections in LP patients needs
further elucidation.
Conclusions
Overall, CLA and HOSF treatments contributed to disease
outcomes during this one-year crossover study, as wit-
nessed by the reduction in number/no surgical procedures
per year in the clinical course of children with LP. After
CLA treatment cases with mildly/moderately aggressive
papillomatosis were clear of viral infections and they recov-
ered after the one-year trial, depending on viral loading.
Cases with highly/severely aggressive papillomatosis had
no surgical procedures during treatments, but after the
treatment period they had repeated surgical procedures
and disease conditions were considered the same. The
effects of HOSF were also restricted to mildly/moderately
aggressive papillomatosis, but were less effective. Prelimin-
ary group findings indicated a significant reduction in the
number of surgical procedures per year for cost effective
treatment. Disease staging was also improved by signifi-
cant down-regulation of papillomatosis and amelioration
of viral infections after CLA treatment. No significant im-
mune enhancement could be demonstrated after CLA
treatment or during the trial. The role of viral loading
(rather than HPV type) in disease outcomes requires fur-
ther clarification. The assumption that there is a link
between IL-10 and clearance or failure to clear viral infec-
tions after CLA treatment in LP patients needs to be con-
firmed or refuted.
The preliminary findings of this study remain a valu-
able contribution to further research for the therapeutic
potential of CLA in HPV-induced LP patients. The
present study paves the way for large scale trials and
prospective development of novel CLA therapy in thetreatment regime of HPV-induced LP patients who may
qualify as candidates.
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